French Registry: Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy

N/ANot Yet RecruitingNCT07428031

Assistance Publique - Hôpitaux de Paris5,000 enrolled

Overview

This study aims to create a registry of patients with hypertrophic cardiomyopathy, a condition characterized by excessive thickening of the heart muscle. This disease can sometimes lead to serious complications. Currently, the prognosis of these patients is mainly determined by clinical and echocardiographic parameters. Detection of myocardial fibrosis using cardiac MRI enables better risk stratification for these patients.

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

Cardiomyopathy Hypertrophic Cardiomyopathies

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age ≥ 18 years 2. Ability to provide informed consent 3. HCM diagnosis referred for CMR assessment. Exclusion Criteria: 1. Patients unable to provide informed consent, 2. Patients with a history of ischemic cardiomyopathy or myocarditis.

Outcomes

Primary Outcomes

To build a score using the "LGE granularity" concept for all-cause mortality prediction in HCM patients.

All-cause mortality using the electronic French National Registry of Death (Institut National de la Statistique et des Etudes Economiques, INSEE registry).

Time frame: From Baseline to 5 years

Central Contacts

Théo PEZEL, Dr

CONTACT

+33 6 68 72 24 89 theo.pezel@aphp.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.